Research Article: Development and Validation of Novel Models Including Tumor Micronecrosis for Predicting the Postoperative Survival of Patients with Hepatocellular Carcinoma
Abstract:
Hepatocellular carcinoma (HCC), one of the most common malignancies, is the third leading cause of cancer-related mortality. Curative hepatectomy remains the most effective treatment for HCC patients. Unfortunately, the postoperative recurrence rate can reach up to % in five years, which causes the dismal survival of HCC patients. Due to the high heterogeneity of HCC, it is challenging to develop clinical models to predict precisely the postoperative prognosis of patients. Several conventional staging systems have been developed to stratify HCC patients with different survival such as the American Joint Committee on Cancer (AJCC) tumor node metastasis (TNM) staging system, Barcelona Clinic Liver Cancer (BCLC) staging classification, Chinese University Prognostic Index (CUPI), Hong Kong Liver Cancer (HKLC) staging system, Japan Integrated Staging (JIS) score, Tokyo score, and Cancer of the Liver Italian Program (CLIP) scoring system; however, there has been no consensus on which system is the optimal.– Besides, these models have limited accuracy in predicting prognosis owing to inherent limitations as the heterogeneity of HCC comprises not only tumor burden and liver function, but also other distinctive factors such as microvascular invasion (MVI).
Introduction:
Hepatocellular carcinoma (HCC), one of the most common malignancies, is the third leading cause of cancer-related mortality. Curative hepatectomy remains the most effective treatment for HCC patients. Unfortunately, the postoperative recurrence rate can reach up to % in five years, which causes the dismal survival of HCC patients. Due to the high heterogeneity of HCC, it is challenging to develop clinical models to predict precisely the postoperative prognosis of patients. Several conventional staging systems have…
Read more